Table 2.
Clinical trials of chloroquine and hydroxychloroquine in patients with COVID-19.
| Register number | Title | Group 1 (sample size) | Group 2 (sample size) | Group 3 (sample size) | Primary indicator | Primary sponsor |
|---|---|---|---|---|---|---|
| ChiCTR2000029898 | Evaluation of the efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate chloroquine in severe patients with novel Coronavirus pneumonia (COVID-19): a randomized, open-label, parallel, controlled trial | Hydroxychloroquine sulfate Day1: first dose: 6 tablets (0.1 g/tablet) , second dose: 6 tablets (0.1 g/tablet) after 6 h ;Day2~5: 2 tablets (0.1 g/tablet), BID (50 patients) | Phosphate chloroquine Day 1-3:500 mg, BID Day 4-5:250 mg, BID (50 patients) | TTCI (Time to Clinical Improvement) | Peking University Third Hospital | |
| ChiCTR2000029988 | Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) | Chloroquine phosphate (40 patients) | None (40 patients) | Time to Clinical Recovery | Zhongnan Hospital of Wuhan University | |
| ChiCTR2000029542 | Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19) | Chloroquine (10 patients) | Conventional management (10 patients) | Viral-negative transforming time 30-day cause-specific mortality | Sun Yat sen Memorial Hospital of Sun Yat sen University | |
| ChiCTR2000029559 | Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19) | Hydroxychloroquine 0.1 oral 2/day (100 patients) | Hydroxychloroquine 0.2 oral 2/day (100 patients) | Starch pill oral 2/day (100 patients) | Renmin Hospital of Wuhan University | |
| ChiCTR2000029609 | A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19) | Oral chloroquine phosphate (59 mild-moderate patients and 14 severe patients) | Oral Lopinavir/ritonavir (59 mild-moderate patients and 14 severe patients) | Chloroquine phosphate plus Lopinavir/ritonavir (59 mild-moderate patients) | Virus nucleic acid-negative transforming time | The Fifth Affiliated Hospital of Sun Yat-Sen University |
| ChiCTR2000029740 | Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients (randomized open-label control clinical trial) | Oral intake hydroxycholoroquine 0.2 twice a day (54 patients) | Conventional therapy (24 patients) | Oxygen index, lung radiography, temperature | The First Hospital of Peking University | |
| ChiCTR2000029741 | Compare the efficacy and safety of chloroquine and lopinavir/ritonavir in patients with mild/general CoVID-19 infection, and establish a standardized treatment plan. | Chloroquine phosphate (56 patients) | Control group (56 patients) | Length of stay, oxygenation index during treatment, all-cause mortality in 28 days | The Fifth Affiliated Hospital Sun Yat-Sen University | |
| ChiCTR2000029803 | A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19) | Hydroxychloroquine, small dose and high dose (80 patients/group) | Abidol hydrochloride, small dose and high dose (80 patients/group) | Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus | Renmin Hospital of Wuhan University | |
| ChiCTR2000029826 | A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19) | 2 tablets phosphoric chloroquine BID (80 patients) | 2 tablets placebo BID (40 patients) | Mortality rate | Jingzhou Central Hospital | |
| ChiCTR2000029837 | A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19) | 2 tablets phosphoric chloroquine BID (80 patients) | 2 tablets placebo BID (40 patients) | Time of conversion to negative novel coronavirus nucleic acid | Jingzhou Central Hospital | |
| ChiCTR2000029868 | Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial | Oral hydroxychloroquine sulfate tablets (100 patients) | Conventional treatment meeting the Guideline (100 patients) | Viral nucleic acid test | Ruijin Hospital, Shanghai Jiaotong University School of Medicine | |
| ChiCTR2000029898 | Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Common Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial | Hydroxychloroquine sulfate Day1: first dose: 6 tablets (0.1 g/tablet) , second dose: 6 tablets (0.1 g/tablet) after 6 h ;Day 2~5: 2 tablets (0.1 g/tablet), BID (50 patients) | Phosphate chloroquine Day 1-3:500 mg, BID Day 4-5:250 mg, BID (50 patients) | Time to Clinical Recovery, TTCR | Peking University Third Hospital | |
| ChiCTR2000029935 | A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) | Conventional treatment combined with Chloroquine Phosphate (100 patients) | Length of hospital stay | HwaMei Hospital, University of Chinese Academy of Sciences | ||
| ChiCTR2000029939 | A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) | Conventional treatment (50 patients) | conventional treatment combined with Chloroquine Phosphate (50 patients) | Length of hospital stay | HwaMei Hospital, University of Chinese Academy of Sciences | |
| ChiCTR2000029988 | Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) | Chloroquine phosphate (40 patients) | None (40 patients) | Time to clinical recovery | Zhongnan Hospital of Wuhan University | |
| ChiCTR2000029992 | A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19) | Chloroquine phosphate 1.0 g x 2 days for the first dose, 0.5 g x 12 days from the third day (40 patients) | Hydroxychloroquine sulfate 0.2 g bid x 14 days (40 patients) | Recommended treatment plan for novel coronavirus pneumonia severe and critical cases (20 patients) | Clinical recovery time, changes in viral load of upper and lower respiratory tract samples compared with the baseline | Zhongshan Hospital Affiliated to Xiamen University |
| ChiCTR2000030031 | A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19) | 2 tablets phosphoric chloroquine BID 80 patients) | 2 tablets placebo BID (40 patients) | Time of conversion to negative novel coronavirus nucleic acid | The Sixth Affiliated Hospital of Guangzhou Medical University | |
| ChiCTR2000030054 | A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19) | Hydroxychloroquine sulfate 0.2 g bid x 14 days a day (30 patients) | First dose of chloroquine phosphate 1 g x 2 days, and the third day was 0.5 g x 12 days (30 patients) | Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan (20 patients) | Clinical recovery time | Zhongshan Hospital Affiliated to Xiamen University |
| ChiCTR2000030417 | Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19) | Chloroquine phosphate aerosol inhalation solution (15 patients) | Water for injection atomization inhalation (15 patients) | Temperature, respiratory symptoms | Harbin infectious diseases hospital | |
| ChiCTR2000030718 | Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19) | Chloroquine phosphate (40 patients) | Regular treatment (40 patients) | Time to clinical recovery | Zhongnan Hospital of Wuhan University | |
| NCT04303507 | Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting | Chloroquine | Placebo | Number of symptomatic COVID-19 infections | University of Oxford |